The diabetes risk was calculated from the analysis of data 23andMe collected from more than 2.5 million customers who opted in to its research.
Genetic risk reports for Alzheimer's disease, Parkinson's disease and Hereditary Thrombophilia included in the FDA authorization, among others.
Called Personal Genome Service, it is touted as an entirely new experience that includes carrier status, wellness, trait and ancestry reports.
The new funds will help the personal genetics company launch new global user experience, grow its sales efforts and therapeutics discovery group efforts.
Toward the same goal, the company has recently hired Genentech veterans Robert Gentleman and Richard Scheller, who led drug discovery there.
It's not really the same thing as 23andMe's original offering which screened for 254 diseases, but it's an important step in the right direction.
The company's mail-order DNA kits provide customers with an overview of their genetic ancestry, and risk assessments for certain diseases based on genetic data.